Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders
GSK announced data for Revolade & Arzerra at EHA meeting, results show potential of improvement in QoL in two haematological conditions.
-
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
GSK & Concert Pharmaceuticals to collaborate on deuterium-containing medicines, incl. CTP-518, a protease inhibitor for the treatment of HIV
-
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1
-
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
GSK & GEN announced that FDA voted 10:3 that ofatumumab, reasonably likely to predict clinical benefit for patients with chronic CLL.
-
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system
GSK announced HHS has placed initial orders for H1N1 vaccine antigen and proprietary adjuvant system, AS03.
-
GlaxoSmithKline update: A (H1N1) influenza vaccine development
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
-
GSK extends strategic collaboration with Aspen
GSK to acquire 16% shareholding in Aspen in exchange for transfer of specialist products and manufacturing facility in Bad Oldesloe, DE.
-
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work
20 charities were formally acknowledged last night for their community-based work, as GSK awards, run in partnership with The King's Fund.
-
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
GSK in agreement to divest full commercial rights for Wellbutrin to BVF for $510 million, subject to Hart-Scott-Rodino clearance in US.
-
GlaxoSmithKline update: influenza A (H1N1)
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
-
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
Primary endpoint achieved in REDUCE study as presented at American Urological Association
-
Emergence of a new H1N1 influenza A strain (swine influenza)
GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.
-
GlaxoSmithKline launches alli® (orlistat 60 mg)
GSK announced, first clinically proven over the counter weight loss aid is available in pharmacies across Europe.
-
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion.
-
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
Creates a new focused HIV business with the sustainability to deliver significant improvements in treatment, access and shareholder value.
-
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
GSK announced, submission of 2 applications to expand the use of lapatinib, therapy regimen for metastatic breast cancer.
-
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
Protection now possible against three pneumococcal strains not covered by currently available vaccine.
-
Cervarix® U.S. regulatory update
GlaxoSmithKline submits final study data to FDA for cervical cancer vaccine
-
GSK publishes 2008 Corporate Responsibility Report
Details on new proposals to tackle diseases of the developing world.
-
GlaxoSmithKline announces sale of shares in Quest Diagnostics Inc.
GSK announces it's sold 5,749,157 shares of common stock, par value of $0.01 per share of Quest Diagnostics Inc.
